Search research articles
Contact Us
Filters
Showing results (11-20 of 124) with videos related to
Page
of 13
Sort By:
The Oncologist
|
September 5, 2020
<sup>68</sup> Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors
Hwan Lee, Jennifer R Eads, Daniel A Pryma
Clinical Nuclear Medicine
|
November 7, 2019
Optimized CT Attenuation and SUV Prediction Thresholds for Differentiating Enostoses From Untreated and Treated Metastases on Attenuation-Corrected 18F-FDG PET/CT
Harrison T Lee, Daniel A Pryma, Ronnie Sebro
Neuroimaging Clinics of North America
|
July 29, 2008
Parathyroid imaging
Saeed Fakhran, Barton F Branstetter, Daniel A Pryma
Breast Cancer Research and Treatment
|
March 19, 2013
Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response
Jessica Anna Cintolo, Julia Tchou, Daniel A Pryma
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 11, 2020
Flare Phenomenon in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas: Potential Contribution from Postoperative Ischemia
S Ali Nabavizadeh, Ilya M Nasrallah, Daniel A Pryma
Cancer
|
June 21, 2014
PET/CT imaging in cancer: current applications and future directions
Michael D Farwell, Daniel A Pryma, David A Mankoff
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2014
Molecular imaging biomarkers for oncology clinical trials
David A Mankoff, Daniel A Pryma, Amy S Clark
Journal of the American College of Radiology : JACR
|
November 10, 2018
A Bright Future for Nuclear Medicine
George M Segall, Daniel A Pryma, Joanna R Fair
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2022
Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study
Marcia S Brose, Daniel A Pryma, Kate L Newbold
Cancer Journal (Sudbury, Mass.)
|
May 16, 2024
Theranostics in Neuroendocrine Tumors
Nadine Mallak, Sophia R O'Brien, Daniel A Pryma, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 124) with videos related to
Sort By:
Page
of 13
The Oncologist
|
September 5, 2020
<sup>68</sup> Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors
Hwan Lee, Jennifer R Eads, Daniel A Pryma
Clinical Nuclear Medicine
|
November 7, 2019
Optimized CT Attenuation and SUV Prediction Thresholds for Differentiating Enostoses From Untreated and Treated Metastases on Attenuation-Corrected 18F-FDG PET/CT
Harrison T Lee, Daniel A Pryma, Ronnie Sebro
Neuroimaging Clinics of North America
|
July 29, 2008
Parathyroid imaging
Saeed Fakhran, Barton F Branstetter, Daniel A Pryma
Breast Cancer Research and Treatment
|
March 19, 2013
Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response
Jessica Anna Cintolo, Julia Tchou, Daniel A Pryma
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 11, 2020
Flare Phenomenon in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas: Potential Contribution from Postoperative Ischemia
S Ali Nabavizadeh, Ilya M Nasrallah, Daniel A Pryma
Cancer
|
June 21, 2014
PET/CT imaging in cancer: current applications and future directions
Michael D Farwell, Daniel A Pryma, David A Mankoff
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2014
Molecular imaging biomarkers for oncology clinical trials
David A Mankoff, Daniel A Pryma, Amy S Clark
Journal of the American College of Radiology : JACR
|
November 10, 2018
A Bright Future for Nuclear Medicine
George M Segall, Daniel A Pryma, Joanna R Fair
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2022
Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study
Marcia S Brose, Daniel A Pryma, Kate L Newbold
Cancer Journal (Sudbury, Mass.)
|
May 16, 2024
Theranostics in Neuroendocrine Tumors
Nadine Mallak, Sophia R O'Brien, Daniel A Pryma, et al.
Page
of 13